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Protein phosphorylationFoxO3 is a member of FoxO family transcription factors that mediate cellular functions downstream of AKT.
FoxO3 phosphorylation by AKT generates binding sites for 14-3-3, which in-turn regulates FoxO3
transcriptional activity and localization. We examine here the functional signiﬁcance of AKT–FoxO3
interaction and further detail the mechanistic aspects of FoxO3 regulation by AKT and 14-3-3. Our data
show that AKT overexpression increases the steady-state levels of FoxO3 protein in a manner dependent on
AKT activity and its ability to bind FoxO3. Characterization of the AKT–FoxO3 interaction shows that the three
AKT phosphorylation-site-recognition motifs (RxRxxS/T) present on FoxO3, which are required for FoxO3
phosphorylation, are dispensable for AKT binding, suggesting that AKT has a docking point on FoxO3 distinct
from the phosphorylation-recognition motifs. Development of a FoxO3 mutant deﬁcient in 14-3-3 binding
(P34A), which can be phosphorylated by AKT, established that 14-3-3 binding and not AKT phosphorylation
per se controls FoxO3 transcriptional activity. Intriguingly, 14-3-3 binding was found to stabilize FoxO3 by
inhibiting its dephosphorylation and degradation rates. Collectively, our data support a model where both
AKT and 14-3-3 positively regulate FoxO3 in addition to their established negative roles and that 14-3-3
availability could dictate the fate of phosphorylated FoxO3 toward degradation or recycling.of Mississippi Medical Center,
el.: +1 601 815 6765; fax: +1
rative Physiology, University of
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FoxO transcription factors are a family of Forkhead box proteins
that include FoxO1 (designated also FoxO1a or FKHR), FoxO3
(FoxO3a/FKHRL1), FoxO4 (AFX) and FoxO6 (for review see [1]).
FoxO proteins are evolutionary conserved transcriptional regulators
controlled by insulin and insulin-like growth factor receptors in
mammals, Caenorhabditis elegans and Drosophila via the PI3K–AKT
pathway [2]. They are similar in sequence and contain a highly
conserved winged-helix domain, which mediates the DNA binding.
FoxO transcription factors coordinate diverse cellular processes
including cell proliferation, apoptosis, reactive oxygen species (ROS)
response and longevity. Some of their target genes include the pro-
apoptotic proteins Bim [3], Bcl-6 [4] and Fas ligand [5], cell cycle
regulators such as p27KIP [3], DNA damage response genes such as
Gadd45 [6] and oxidative stress response proteins such as MnSOD [7],
caveolin-1 [8] and catalase [9]. Given their role in proliferation and
apoptosis and the frequent deregulation of their upstream effectors incancer, FoxO proteins and their target genes are considered attractive
targets for cancer therapy [10–12].
While FoxO transcription factors display functional redundancy,
some variations in their function have been noted. In mouse knockout
models, the FoxO proteins have functional diversity; FoxO1 knockout
mice are non-viable while FoxO3 knockout mice are viable, but display
abnormal ovarian development [13,14]. The distribution of FoxO
isoforms also varies: FoxO6 and FoxO4 mRNAs are expressed in select
tissues, while FoxO3 and FoxO1 mRNAs are ubiquitously expressed,
though at varying levels in different tissues [15]. FoxO regulation by
post-translational modiﬁcations also differs. For example, all FoxO
proteins are phosphorylated by AKT; however, FoxO6 lacks the third
phosphorylation site present in the other isoforms [1,16]. Also, only
FoxO3 can be phosphorylated and regulated by IκB kinase at Serine 644
[17]. The majority of the research has been focused so far on FoxO1 and
FoxO3 isoforms because of their ubiquitous expression pattern and for
being the closest homologues of the C. elegans FoxO, Daf-16, which was
originally shown to mediate signaling downstream of the insulin
receptor–PI3K–AKT pathway [1,2,18].
FoxO3 is regulated by various post-translational modiﬁcations
including acetylation, ubiquitination and phosphorylation (reviewed
in [1,19]). Phosphorylation, along with a Nuclear Exclusion Sequence
(NES) and a Nuclear Localization Sequence (NLS), dictates the
subcellular localization of FoxO proteins. Growth factor responsive
kinases such as AKT, SGK, CK1 and DYRK1A phosphorylate FoxO
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regulated kinases such as MST1 and JNK can promote their
localization to the nucleus [20,21].
Many experimental studies have focused on the regulation of FoxO
proteins by the PI3K–AKT pathway [5,22–25]. These studies demon-
strated that AKT phosphorylates FoxO proteins on three residues,
Threonine 32, Serine 253 and Serine 315 (for human FoxO3). This
phosphorylation leads to negative FoxO regulation by causing its
nuclear exclusion, which is mediated by 14-3-3 proteins and results in
inhibition of FoxO transcriptional output. Additional details of this
mechanism were discovered through studying the C. elegans
homologue, Daf-16, showing that binding of a 14-3-3 dimer to the
transcription factor blocked its DNA binding [26]. This effect of 14-3-3
was conﬁrmed later with human FoxOs [27,28], showing that 14-3-3
binding to the aminoterminal sites blocks FoxO-DNA interactions.
Following phosphorylation of FoxO by AKT and cytoplasmic
retention by 14-3-3, FoxO can be degraded by the proteasome [29].
This negative regulation of FoxO can be inhibited by the addition of
the PI3K inhibitor, LY294002. Later studies established Skp2 as the
probable E3 ligase for FoxO1 [30] and that FoxO1 could be rescued
from degradation by dephosphorylation by PP2a, or a PP2a-like
enzyme [31]. Besides the negative regulation by the PI3K–AKT
pathway, the mitogen-activated protein kinase, ERK, was shown to
phosphorylate FoxO3 at residues S294, S344 and S425, leading to its
degradation by an MDM2–ubiquitin–proteasome pathway [32–34].Fig. 1. AKT and 14-3-3ζ stably bind FoxO3 and increase its steady-state protein levels.
phosphorylation sites. (B) HEK-293T cells were transfected for 24 hours with HA-FoxO3 to
showing expression of HA-FoxO3, T32-phosphorylated FoxO3 and the GST-fusion proteins i
following GST-pull-down is presented in the right panel. (C and D) HEK-293T cells were tra
(lanes 1–3) or 48 hours (lanes 4–6) and expression of the transfected proteins in total cellAs noted above, AKT phosphorylates FoxO3 on three residues
(Fig. 1A). These residues are located at an AKT phosphorylation-
recognition motif, RxRxxS/T [35,36], with the ﬁrst site (T32) also
containing the 14-3-3 consensus-binding motif RSxpS/TxP [37,38].
Mutation of all three AKT phosphorylation sites of FoxO3 has been
shown to give rise to a constitutively active form, which is primarily
located in the nucleus and can reverse and/or suppress cellular
transformation [5,39–41]. The individual AKT phosphorylation sites
have been further analyzed by single mutations, suggesting that the
S256 site on FoxO1(S253 in FoxO3) is necessary for thephosphorylation
of the T24 site (T32 in FoxO3) [42,43]. Since the AKT-phosphorylation
site mutants show dominant negative effects on AKT activity, it is not
clear which one of the observed functions of themutants is the result of
FoxO transcriptional activity and which one stems from AKT inhibition.
AKT was shown to have stable interactions with some of its
substrates, including FoxO3 [44–46]. Functionally, AKT binding was
shown to have both negative and positive effects on its substrates,
depending on the target. For example, AKT binding results in
inhibition of Par-4 and Merlin activities [47,48], while increasing the
activities of VCP and actin [49,50]. The mechanistic aspects of AKT
interaction with its substrates are, however, largely unknown
[44,51,52]. The RxRxxS/T phosphorylation-recognition motif was
determined by deﬁning the substrate speciﬁcity of AKT [35] and by
screening peptide and protein libraries [36] and was shown to be
necessary for the phosphorylation of all of its known substrates. A(A) Depiction of mammalian and C. elegans FoxO isoforms and corresponding AKT
gether with GST (lane 1), GST-AKT (lane 2) or GST-14-3-3ζ (lane 3). Immunoblotting
n total cell extracts is presented in the left panel and the recovery of the same proteins
nsfected as in B with wildtype FoxO3 (C) or FoxO3 3XA (T32A/S253A/S315A, D) for 24
extracts was examined by immunoblotting.
Fig. 2. AKT stabilizes both the nuclear and cytoplasmic fractions of FoxO3. HEK-293T
cells transfected for 24 hours with control vector (lanes 15–18), HA-FoxO3 (lanes 7–
14) or HA-FoxO3 3XA mutant (lanes 1–6) together with empty control vector (lanes 5,
6, 13, 14, 17, 18) GST control (lanes 3, 4, 9, and 10), GST-AKT (lanes 1, 2, 7, 8, 15, and 16)
or GST-14-3-3ζ (11 and 12) were fractionated to nuclear (N) and cytoplasmic
(C) fractions. Immunoblot showing total FoxO3, pT32-FoxO3 and GST-fusion protein
expression is presented. Alpha tubulin immunoblot served to verify the purity of the
fractionations.
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to the AKT kinase pocket in co-crystallization studies [53]. However a
critical question remains regarding the role of this motif in mediating
AKT–substrate interactions [52]. In this respect, it appears that the
Ser/Thr residue itself is not obligatory for the binding since many
substrates with alanine substitution at the phosphorylation site still
bind to AKT. The role of the arginines in the binding has not been
established. This question is of special signiﬁcance since deﬁning the
binding requirements may offer new ways for targeting the pathway
by blocking AKT–substrate interactions, allowing the identiﬁcation of
more substrate-speciﬁc inhibitors than the currently available in-
hibitors that primarily target AKT kinase activity.
The complex nature of AKT and 14-3-3 interactions with their
substrates as well as the functional aspects of these interactions on the
activity of their substrates led us to further examine the roles of AKT and
14-3-3 in the regulation of FoxO3. We provide here a more detailed
characterization of AKT–FoxO3 interaction by establishing that the AKT
phosphorylation-recognitionmotif, RxRxxS, while critical for the ability
of AKT to phosphorylate FoxO3, is negligible for AKT–FoxO3 binding.
This ﬁnding points to the existence of a docking point on Foxo3 for AKT
binding, distinct from the established phosphorylation recognition
motif. Furthermore, our data suggest a positive regulation of FoxO3 by
both 14-3-3 and AKT, with AKT acting via increasing FoxO3 steady-state
protein levels and 14-3-3 via protecting FoxO3 fromdephosphorylation
and degradation. Thus, our ﬁndings propose a more complex mode of
regulation of FoxO3 by AKT and 14-3-3 indicating on positive roles in
addition to the reported negative roles.
2. Materials and methods
2.1. Cell lines, tissue culture and antibodies
293T cells and HepG2 cells were maintained in high-glucose DMEM
(Invitrogen) with either 10% Newborn Calf Serum (293T) or 10% Fetal
Bovine Serum (HepG2) in a humidiﬁed incubator with 5% CO2. Cells for
Luciferase Reporter Assays were cultured in 60 mm Nunc plates. All
other experiments were performed in 100 mm Corning plates. The
following antibodies were purchased from Cell Signaling Technologies:
FoxO3 (#9467), pT32FoxO3 (#9464), pS256FoxO3 (#9466), AKT
(#9272), pS473AKT (#9271), and GST (#2624). Tubulin monoclonal
antibody was purchased from Sigma–Aldrich. The HAmouse monoclo-
nal antibody was produced using the 12CA5 hybridoma. Secondary
horseradish-conjugated anti-mouse and anti-rabbit antibodies were
purchased from Jackson ImmunoResearch Laboratories.
2.2. Plasmid constructs and transient transfections
pcDNA3.1-FoxO3-HA, a gift from Dr. Karen Arden (UCSD), and
pEBG-GST-14-3-3ζ and pEBG-GST-AKT, a gift from Dr. Jim Woodgett
(Samuel Lunenfeld Research Institute) have been previously de-
scribed [26,54,55]. pcDNA3.1-FoxO3-HA and pEBG-GST-AKT mutants
and pcDNA3.1-FoxO3 fragments used in this study were created using
QuikChange site-directed or multi-site-directed mutagenesis kits
(Stratagene) and were conﬁrmed by full-length sequencing. FHBE-
Luciferase reporter for FoxO was obtained from Addgene (submitted
by Michael Greenberg's lab [5]). pTK/Renilla Luc reporter was a gift
from Dr. Arun Rishi (Wayne State University). Transient transfections
were performed using FuGENE HD (Roche) according to the
manufacturer's instructions.
2.3. Cell extraction, fractionation and Western blot analysis
Cellswere lysed in buffer containing 50 mMTris–Cl, pH7.5, 100 mM
NaCl, 1% Triton, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 mM β-
glycerolphosphate, 2 mM Na2VO4 and protease inhibitors and cleared
by centrifugation. For nuclear/cytoplasmic fractionation, we used theNE-PER fractionation kit from Pierce according to the manufacturer's
instructions. Protein extracts were separated using SDS-PAGE, trans-
ferred to PVDF membranes (0.2 uM Immun-Blot, BioRad) and were
immunoblotted using the indicated antibodies followed by ECL. The
blots were analyzed using ChemiDoc digital imaging system (BioRad).
2.4. Protein–protein interaction studies
Cells expressing the indicated vectors were lysed and proteins
were extracted as detailed above. Equal amounts of protein (1–2 mg)
were incubated with GSH beads (Amersham/GE Healthcare) for
90 minutes followed by 2× washes with lysis buffer, 1× wash with
lysis buffer containing 0.5 M LiCl and 2× washes with buffer
containing 40 mM Tris-Cl, pH 7.5, 0.1 mM EDTA and 5 mM MgCl2.
For the last wash, the GSH beads were transferred to a new tube and
the proteins were eluted using SDS-PAGE sample buffer at 95 °C for
5 minutes. Total cell extracts were saved from each sample to verify
protein expressions.
2.5. FoxO transcription reporter assay
HepG2 cells were co-transfected with the FHBE-Luciferase vector
containing FoxO binding sites and the pTK/Renilla Luc control vector
together with the indicated pcDNA3.1 control or FoxO3 expression
vectors in 60 mm plates for 48 hours. Cells were lysed in 200 μL lysis
buffer and 50 μl protein extracts were distributed to a white ﬂat-
bottom 96-well plate. Equal amounts of the Dual-Glo Luciferase Assay
System (Promega, E2920) buffer A were added to each well and
incubated for 15 minutes before reading. The Stop and Glo reagent
was added and incubated for 15 minutes before reading Renilla
activity. Luminescence was read with a BioTek Synergy 2 using Gen5
software. Expression of FoxO3 variants in each experiment was
veriﬁed by immunoblotting the cell extracts.
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3.1. 14-3-3ζ and AKT bind FoxO3 and increase its steady-state protein
levels
The binding of FoxO proteins to 14-3-3 has been well established
[5,26,27] and FoxO binding to AKT also has been reported [45]. To
conﬁrm the interaction with AKT, HA-FoxO3 was co-transfected with
GST control or with GST-tagged AKT or 14-3-3ζ in 293T cells for
24 hours and a GST pull-down was performed (Fig. 1B). These
experiments conﬁrmed that both AKT and 14-3-3ζ were capable of
stably binding FoxO3. Interestingly, while 14-3-3ζ was able to pull-
down phosphorylated FoxO3, no FoxO3 phosphorylation was
detected in AKT pull-downs (Figs. 1B and 2C, p-FoxO blot, compare
lanes 2 and 3). In addition, examination of FoxO3 expression levels in
total cell extracts demonstrated that co-expression of AKT increased
FoxO3 steady-state protein levels when compared to the GST control
(Fig. 1B, total cell extract blot, compare lanes 1 and 2). To further
explore this observation, FoxO3 was co-expressed with AKT or 14-3-
3ζ for 24 or 48 hours (Fig. 1C). While longer co-expression with AKT
did not notably increase FoxO3 levels (Fig. 1C, compare lanes 2 and 5),
the longer co-expression with 14-3-3ζ signiﬁcantly increased theFig. 3. The ability of AKT to bind and increase FoxO3 steady-state protein levels is not depen
ﬁgure: wildtype FoxO3; indicated are the three AKT phosphorylation sites T32, S253 and S3
substitutions at the three RxR AKT-phosphorylation-recognition motifs. (B and C) HEK-29
(lanes 4–6) or HA-FoxO3 3XA (lanes 7–9) mutant together with GST, GST-AKT or GST-14-3-
and the GST-fusion proteins in total cell extracts are presented in B and the recoveries of th
were transfected as in B with HA-FoxO3 (lanes 1–3), HA-FoxO3 3XA (lanes 4–6), HA-FoxO3
HA-FoxO3 3X-RxR mutant (lanes 13–15) and expression of the transfected proteins in totasteady-state levels of both phosphorylated and total FoxO3 proteins
(Fig. 1C, compare lanes 3 and 6). Importantly, while AKT was able to
bind and increase the steady-state levels of both, wildtype FoxO3 and
a mutant lacking the three AKT phosphorylation sites, FoxO3 3XA, 14-
3-3ζ was only able to bind and stabilize the wildtype form (Fig. 1D).
To examine which pool of FoxO3 was stabilized by AKT, cells
expressing FoxO3 or the FoxO3 3XAmutant, alone or together with GST
control, GST-AKT or GST-14-3-3ζ were fractionated 24 hours after
transfection to cytoplasmic and nuclear fractions and examined for total
FoxO3 and p-FoxO3 levels (Fig. 2). These experiments showed that AKT
expression increased the steady-state protein levels of FoxO3 and the
3XA mutant in both nuclear and cytoplasmic fractions. p-FoxO3,
however, was only increased in the cytoplasm, corroborating previous
observations that p-FoxO is being shuttled rapidly out of the nucleus.
3.2. AKT binding to FoxO3 and its ability to enhance FoxO3 steady-state
protein levels are not dependent on the RxRxxS/T motif
After conﬁrming that AKT stably binds FoxO3,wewanted to further
characterize the AKT–FoxO3 interaction. To examine the role of the
three AKT phosphorylation recognition motifs of FoxO3, we substitut-
ed the arginines at positions −3 and −5 of the phosphorylationdent on the three FoxO3 RxRxxS/T motifs. (A) A depiction of FoxO3 variants used in this
15. 3XA, alanine substitutions at the three AKT phosphorylation sites. 3X-RxR, leucine
3T cells were transfected for 24 hours with HA-FoxO3 (lanes 1–3), HA-FoxO3 3X-RxR
3ζ. Immunoblots showing expression of HA-FoxO3, T32-phosphorylated FoxO3, tubulin
e same proteins following GST-pull-down are presented in C. (D and E) HEK-293T cells
1X-RxR (R27/29L, lanes 7–9), HA-FoxO3 2X-RxR (R27/29L, R248/250L, lanes 10–12) or
l cell extracts (D) and in GST-pull-downs (E) is presented.
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motif (illustrated in Fig. 3A). These arginines were shown to be critical
for the ability of AKT to phosphorylate peptide substrates [35,36]. As
presented in Fig. 3, co-immunoprecipitation experiments demonstrat-
ed that mutations at the RxRxxS/T motifs of FoxO3 abolish binding to
14-3-3ζ but have little effect on AKT binding (Fig. 3C, compare lanes 3,
6 and 9 for 14-3-3ζ binding and lanes 2, 5 and 8 for AKT binding; note
that the expression levels of the 3XA and 3X-RxR mutants are
signiﬁcantly lower than wildtype FoxO3, Fig. 3B, compare lanes 1–3,
4–6 and 7–9). In addition, AKT was still able to increase the steady-
state protein levels of the RxR and 3XAmutants, while the effect of 14-
3-3ζ was abolished (Fig. 3B). These results suggest that the RxRxxS/T
motifs do not play a central role in AKT–FoxO3 interaction or the ability
of AKT to increase FoxO3 steady-state protein levels.
The RxR motifs were also examined individually and AKT was
found to bind and increase the steady-state protein levels of the
examined mutants to a comparable extent, indicating that these sites
play little role in AKT binding or its effect on FoxO3 levels (Figs. 3D
and E, compare lanes 2, 5, 8, 11 and 14; note that in this experiment
we reduced the DNA amounts of wildtype FoxO3 during transfection
to achieve comparable expression levels of wildtype and mutant
FoxO3 forms). In contrast to AKT, 14-3-3ζ exhibited diminished
binding to the RxR mutants and was unable to increase their steady-
state protein levels (Figs. 3D and E, compare lanes 3, 6, 9, 12 and 15),
indicating that the RxR motifs are critical for this positive regulatory
role of 14-3-3 on FoxO3.
3.3. The ability of AKT to increase FoxO3 steady-state protein levels
involves the N-terminal protein segment
Since the RxR motif mutants were not capable of eliminating the
stabilizing effect of AKT on FoxO3, we created several N-terminal
FoxO3 deletion variants that included mutations at the RxR motif
(illustrated in Fig. 4A). As can be seen in Fig. 4B, the 1–260 N-terminus
fragment of FoxO3 is sufﬁcient for the AKT-induced steady-state
protein level increase (Fig. 4B, compare lanes 4 and 5). This increase
was not dependent on the RxR motif, similarly to the results obtained
with full-length FoxO3 (Fig. 4B, compare lanes 7, 10, and 13with lanesFig. 4. The ability of AKT to increase FoxO3 steady-state protein levels involves the N-termina
fragment containing leucine substitutions at the RxR AKT-phosphorylation recognition mo
FoxO3 1–260 (lanes 4–6), FoxO3 1–260 RxRT32 (R27/29L, lanes 7–9), FoxO3 1–260 RxRS253
13–15) together with GST, GST-AKT or GST-14-3-3ζ. Immunoblots showing expression of Fo
cell extracts are presented.8, 11, and 14). The ability of 14-3-3ζ to increase steady-state levels of
FoxO3 was eliminated in the fragments, suggesting that 14-3-3ζ
needs the full-length FoxO3 protein for this effect (Fig. 4B, compare
lanes 4, 7, 10, and 13 with lanes 6, 9, 12, and 15).
It has been previously reported that the second AKT phosphory-
lation residue on FoxO1, S256, is necessary for the subsequent
phosphorylation of the remaining FoxO residues by AKT [43]. This
study used a FoxO1 mutant containing an alanine substitution at the
S256 site. However, there is a possibility that the FoxO1 S256Amutant
limits the phosphorylation of the other sites by serving as a dominant
negative form for AKT in trans rather than acting on FoxO1 itself in cis.
To examine this question, we mutated the corresponding phosphor-
ylation sites individually and in tandem on the 1–260 FoxO3 fragment
(Fig. 5A) and assayed its phosphorylation on each of the sites (Fig. 5B).
These results show that the 1–260 fragment is phosphorylated at both
the T32 and S253 residues to the same extent as full-length FoxO3
(Fig. 5B, compare lanes 2 and 10), indicating that the C-terminus
truncation that eliminates the third AKT phosphorylation site, S315,
does not affect T32 and S253 phosphorylation. In addition, mutation
of T32 did not have signiﬁcant effect on S253 phosphorylation (Fig. 5B,
compare lanes 10 and 14) and vice versa, mutation of S253 did not
signiﬁcantly affect T32 phosphorylation (Fig. 5B, compare lanes 10
and 18), suggesting that the phosphorylations at these sites are
independent of each other in the context of the 1–260 fragment.
Interestingly, an ATP-binding pocket AKT mutant, AKT K179M used as
a control in these experiments, failed to increase the steady-state
levels of FoxO3 in contrast to wildtype AKT (Fig. 5B, compare lanes 2,
6, 10, 14 18, and 22 with lanes 3, 7, 11, 15, 19, and 23), suggesting that
an intact, kinase active AKT is needed for this function as further
detailed below.
3.4. AKT activation is required for FoxO3 binding and for increasing
FoxO3 steady-state protein levels
To further understand the mechanism of AKT–FoxO3 binding and
the ability of AKT to increase FoxO3 protein levels, we examined the
effects of inactivating AKT mutations on its binding to FoxO3 (Fig. 6).
As seen in Fig. 6, an inactivating mutation in the ATP binding pocketl segment. (A) Depiction of FoxO3 variants used in this ﬁgure: 1–211, 1–260 and 1–260
tifs. (B) HEK-293T cells were transfected for 24 hours with FoxO3 1–211 (lanes 1–3),
(R248/250L, lanes 10–12) or FoxO3 1–260 2X-RxR fragment (R27/29L, R248/250L, lanes
xO3 fragments, T32-phosphorylated FoxO3, tubulin and the GST-fusion proteins in total
Fig. 5. FoxO3 T32 and S253 AKT phosphorylation sites are phosphorylated by AKT independent of each other. (A) Depiction of FoxO3 variants used in this ﬁgure: 1–260 fragment
containing alanine substitutions at the T32 and S253 AKT phosphorylation sites. (B) HEK-293T cells were transfected for 24 hours with HA-FoxO3 (lanes 1–4), FoxO3 1–211 (lanes
5–8), FoxO3 1–260 (lanes 9–12), FoxO3 1–260 T32A (lanes 13–16), FoxO3 1–260 S253A (lanes 17–20) or FoxO3 1–260 2A fragment (T32A/S253A, lanes 21–24) together with GST,
GST-AKT, GST-AKT K179M (an inactive, dominant negative AKT form) or GST-14-3-3ζ. Immunoblots showing expression of FoxO3, T32-phosphorylated FoxO3, S253-
phosphorylated FoxO3, tubulin and the GST-fusion proteins in total cell extracts are presented.
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sites (T308/S473) interfered with the ability of AKT to bind FoxO3
(Fig. 6B, compare lanes 2 and 3 with 4 and 5 for wildtype FoxO3, and
lanes 7 and 8 with 9 and 10 for FoxO3-3XA mutant and Fig. 6C,
compare lane 2 with 3 and 4). In addition, these mutations abolished
the ability of AKT to increase FoxO3 steady-state protein levels
(Fig. 6A, compare lanes 2 and 3 with 4 and 5, and 7 and 8 with 9 and
10). Notably, expression of the inactive AKTmutants resulted in lower
FoxO3 phosphorylation levels, consistent with previous reports
showing dominant negative effects of inactive AKT mutants on
endogenous AKT [56]. Though these ﬁndings suggest that AKT
needs to be active for FoxO3 binding, it is possible that the mutations
result in conformational changes that indirectly affect the binding or
that they result in altered AKT localization. To address this point, we
examined the effect of the PI3K inhibitor LY294002 on AKT binding to
FoxO3 (Fig. 6D). As seen in this ﬁgure, LY294002 treatment resulted in
a marked decrease in FoxO3 phosphorylation, both in control GST-
expressing cells and in the GST-AKT expressing cells, indicating on
inhibition of AKT activity (Fig. 6D, left panel, compare lanes 2 and 5
with 1 and 4). Importantly, the AKT inhibition was accompanied by a
signiﬁcant dissociation of the AKT/FoxO3 complex (Fig. 6D, rightpanel, compare lanes 1 and 2), indicating that only active AKT binds to
FoxO3, corroborating the results obtained with the inactivating AKT
mutations. It still remains to be determined, however, whether the
ability of AKT to increase FoxO3 steady-state protein levels depends
on AKT binding to FoxO3 or strictly on AKT activity, since the AKT
mutants we used and the LY294002 treatment have not distinguished
between these two possibilities. Nonetheless, it is clear from the data
that this effect is independent of the ability of AKT to phosphorylate
FoxO3 itself as demonstrated by the effect of AKT on FoxO3 3XA and
3X-RxR mutants lacking the AKT phosphorylation sites.
3.5. 14-3-3ζ binding protects FoxO3 from dephosphorylation
To elucidate the mechanism of 14-3-3ζ-induced increase in total
and phosphorylated FoxO3 levels (Fig. 1), we examined the effect of
14-3-3ζ on FoxO3 protein half-life in the presence of the protein
translation inhibitor, cycloheximide (Fig. 7). The proteasome inhibitor
MG132 was used in these experiments to prevent proteasome-
mediated degradation in order to determine whether the increase in
phosphorylated-FoxO3 was due to protection from degradation or
dephosphorylation. As seen in Fig. 7, basal phosphorylated-FoxO3
Fig. 6. Intact activation sites and ATP binding pocket are required for AKT to bind FoxO3 and enhance its steady-state protein levels. (A and B) HEK-293T cells were transfected for
24 hours with HA-FoxO3 (lanes 1–5) or HA-FoxO3 3XA (lanes 6–10) together with GST, GST-AKT (4 or 6 μg DNA), GST-AKT K179M or GST-AKT K179M/2A (K179M/T308A/S473A).
Immunoblots showing expression of HA-FoxO3, T32-phosphorylated FoxO3, tubulin and the GST-fusion proteins in total cell extracts are presented in A and the recoveries of HA-
FoxO3 and GST-fusion proteins following GST-pull-down are presented in B. (C) HEK-293T cells were transfected for 24 hours with HA-FoxO3 together with GST (lane 1), GST-AKT
(lane 2), GST-AKT 2A (T308A/S473A, lane 3) or GST-AKT K179M (lane 4). Immunoblots showing expression of HA-FoxO3 and the GST-fusion proteins in total cell extracts are
presented in the left panel and the recoveries of HA-FoxO3 and GST-fusion proteins following GST-pull-down are presented in the right panel. (D) HEK-293 cells were transfected
with HA-FoxO3 together with GST control (lanes 4–6) or GST-AKT (lanes 1–3) and 24 hours after transfection the media was replaced with fresh complete media (lanes 1 and 4) or
media lacking serum supplemented with vehicle (lanes 3 and 6) or with 20 μM LY294002 (lanes 2 and 5). Immunoblots showing recovery of HA-FoxO3 following GST-pull-down are
presented in the right panel. Also shown are GST-fusion protein recoveries and expression of HA-FoxO and p-FoxO3 in total cell extracts (left two panels).
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in those expressing the GST control (Fig. 7, compare lanes 1 and 11).
Following 7-hour cycloheximide treatment, p-FoxO3 levels decreased
in both control and GST-14-3-3ζ expressing cells (Fig. 7, compare
lanes 1–5 with lanes 11–15). Treatment with MG132 resulted in
increased p-FoxO3 levels in the control, GST expressing cells, indicating
that phosphorylated FoxO3 is subject to degradation.More importantly,
while p-FoxO3 levels gradually decreased following cycloheximide
treatment inGST-expressing control cells, nodecrease in p-FoxO3 levels
was observed in GST-14-3-3ζ expressing cells treated with MG132
(Fig. 7, compare lanes 6–10 with lanes 16–20), suggesting that 14-3-3ζ
primarily protects FoxO3 from dephosphorylation.
To further investigate this effect of 14-3-3ζ on phosphorylated-
FoxO3 and to support the idea that 14-3-3ζ inhibits FoxO3
dephosphorylation, we generated a FoxO3 mutant, FoxO3 P34A.This mutant was designed to enable regulation by AKT (binding,
phosphorylation and stabilization), but to interfere with 14-3-3
binding. This approach took advantage of the 14-3-3-binding re-
quirements, which necessitates a proline at the +2 position of the
phosphorylated residue, RSxpS/TxP [37,57], P34 in FoxO3. Important-
ly, the +2 position has been shown to not have a signiﬁcant effect on
the ability of AKT to phosphorylate peptide substrates [36]. As seen in
Fig. 8, the P34A FoxO3 mutant was indeed able to bind AKT to the
same extent as wildtype FoxO3 (Fig. 8B, compare lanes 2 and 5), but
showed a dramatic decrease in its ability to bind 14-3-3 (Fig. 8B,
compare lanes 3 and 6), demonstrating the critical role of the proline
at position 34 for 14-3-3 binding, while not affecting binding to AKT.
In addition, AKT was able to increase the steady-state protein levels of
both the P34Amutant and wildtype FoxO3 (Fig. 8A, HA-blot, compare
lane 1 with 2 and lane 4 with 5), while 14-3-3 affected wildtype
Fig. 7. 14-3-3ζ binding protects FoxO3 from dephosphorylation. HEK-293T cells were
transfected for 24 hours with HA-FoxO3 together with GST (lanes 1–10) or GST-14-3-
3ζ (lanes 11–20). Cells were treated with vehicle (lanes 1–5 and 11–15) or 10 μM
MG132 (proteasome inhibitor, lanes 6–10 and 16–20) for 2 hours, followed by
treatment with 25 μg/ml cycloheximide (protein translation inhibitor) for the indicated
periods. Cells were lysed and equal protein amounts were analyzed for total and T32-
phosphorylated FoxO3 levels by immunoblotting. Also presented are GST and tubulin
immunoblots showing equal protein loading.
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and lane 4 with 6). This result was similar to the results obtained with
the AKT phosphorylation site mutants that did not bind 14-3-3, i.e. the
RxR and the 3XA FoxO3 mutants. Thus, these results established the
P34Amutant as a useful tool for studying the role of 14-3-3 binding in
the stabilization of phosphorylated-FoxO3, without seemingly affect-
ing its regulation by AKT. To this effect, the FoxO3 P34A mutant
exhibited diminished steady-state phosphorylation at the S253 site
(Fig. 8A, p-FoxO blot, compare lanes 1–3 with 4–6). Importantly,
addition of the phosphatase inhibitor calyculin A that inhibits PP2A
and PP1A was able to restore phosphorylation, especially in the
presence of AKT (Fig. 8A, compare lanes 7–9 with 10–12), suggesting
that the mutant is impaired in its dephosphorylation rate rather than
its accessibility to AKT. Calyculin A was selected for these experiments
since PP2Awas shown in previous studies to be themain phosphatase
regulating FoxO dephosphorylation at the AKT phosphorylation sites
[31,58]. Similar results were obtained using antibodies for the T32 site
(data not shown); however, since P34 could be part of the recognition
site of the antibody, only the results obtainedwith the pS253 antibody
offer conclusive evidence. Overall, our ﬁndings support the view that
14-3-3ζ binding protects FoxO3 from dephosphorylation, which in
turn results in increased steady-state FoxO3 protein levels, thus
offering a positive role of 14-3-3ζ in FoxO3 regulation in addition to its
established negative role.
3.6. Constitutive transcriptional activity of FoxO3 P34A mutant suggests
that 14-3-3 binding rather than AKT phosphorylation is the key factor in
negative FoxO regulation
To determine the functional signiﬁcance of 14-3-3 binding to
FoxO3, we compared the transcriptional activity of FoxO3 P34A
mutant with that of wildtype FoxO3 and the 3XA FoxO3 mutant
lacking the three AKT phosphorylation sites (Figs. 8C and D). These
experiments show that wildtype FoxO3 activity can be suppressed by
insulin treatment in HepG2 cells, while the 3XA mutant exhibits
constitutive activity, as previously reported. The P34A FoxO3 mutant
exhibited as high activity as the 3XA mutant, and was not affected by
insulin treatment, providing evidence that the P34A mutation results
in constitutive activation of FoxO3 (Fig. 8C). In addition, even co-expression with AKT, which results in a strong inhibition of wildtype
FoxO3, failed to inhibit the transcriptional activity of the P34Amutant
(Fig. 8D), demonstrating its usefulness in studymodels that have high
AKT activity. Indeed, we obtained similar results in PC3 prostate
cancer cells that carry high AKT activity due to inactivation of the
PTEN lipid phosphatase (data not shown). These results suggest that
14-3-3 binding rather than AKT phosphorylation per se is the key
factor in the negative regulation of FoxO3 transcriptional activity.
4. Discussion
The results presented here provide several new ﬁndings that extend
ourunderstanding of the complex regulation of FoxO3byAKT and14-3-
3 and offer a newmodel of FoxO regulationwhere both 14-3-3 and AKT
have positive roles in FoxO3 regulation besides their established
negative roles (Fig. 9). In this model, we propose that active AKT
binds FoxO3 through a docking point distinct from the RxRxxS
consensus AKT-phosphorylation recognition motif and increases the
steady-state levels of FoxO3protein, either directly or indirectly through
the activation of other downstream targets. Sincewe have not observed
binding of phosphorylated-FoxO3 with AKT, we propose that following
FoxO phosphorylation, AKT–FoxO complexes dissociate, possibly as a
result of competitionwith 14-3-3. The phosphorylation by AKTdoes not
promote by itself the inhibition of FoxO3 transcriptional activity; rather,
14-3-3 binding serves as the key point in this inhibition, presumably via
blocking FoxO3–DNA binding and promoting its nuclear exclusion. At
the same time, however, 14-3-3 protects FoxO3 from dephosphoryla-
tion anddegradation, thusmaintaining a cytoplasmic pool of FoxO3 that
can be recycled. Hence, the availability of free 14-3-3 in the cell could
dictate the rate of FoxO3 inactivation and also the fate of phosphory-
lated-FoxO3, either toward degradation or recycling.
The proposed model is supported by results demonstrating that
AKT binding to FoxO3 is not dependent on the AKT phosphorylation
recognition motif RxRxxS/T, as far as neither mutating the phosphor-
ylation site or the arginines has affected FoxO3–AKT interaction. This
ﬁnding suggests that AKT has a docking point on FoxO3, which is
different from the established phosphorylation recognitionmotif. This
is a signiﬁcant ﬁnding that could be relevant also to other AKT
substrates that were reported to stably associate with AKT. Currently
our understanding of AKT binding to its substrates is very limited and
the domains in AKT or the substrate thatmediate the binding have not
been deﬁned [46,51,52]. Crystallography analyses of AKT kinase
domain co-crystallized with a substrate peptide pinpointed residues
in the AKT kinase pocket that interact with the arginines in the
substrate peptide; however, their role in AKT-target binding has not
been examined [53,59,60]. Also, it has not been determined whether
these interactions are of high enough afﬁnity to mediate the observed
stable interaction of AKT with its substrates. Our results clearly show
that mutation of the phosphorylation recognition motif does not
affect the binding of AKT to FoxO3; thus at least in the case of FoxO3,
there appears to be a different domain on FoxO3 that mediates the
binding. Surprisingly, however, although the phosphorylation recog-
nition motif was not required for AKT binding, AKT inhibition and
mutations that impair its activation or catalytic function blocked the
binding to FoxO3. This ﬁnding suggests that AKT activation state and
the examined residues directly or indirectly contribute to the
interaction. One possible explanation for the observed results is that
AKT autophosphorylation plays a role in attaining or maintaining the
right conformation for FoxO3 binding [61]. In this regard, AKT binding
to several of its substrates has been shown to be impaired by the K179
or the T308/S473 mutations (e.g., SETDB1, B23/NPM and Merlin)
[48,62,63]; however, in the case of several other substrates, no effect
of these mutations was seen with regards to substrate binding (e.g.,
Bad and PEA-15) [64,65]. Detailed structural studies will be probably
required to resolve these questions and to reveal the mechanistic
aspects of AKT interactions with FoxO and its other targets.
Fig. 8.Mutation of FoxO3 P34 diminishes binding to 14-3-3ζ and results in a constitutively active form. (A and B) HEK-293T cells were transfected for 24 hours with HA-FoxO3 (lanes
1–3 and 7–9) or HA-FoxO3 P34A mutant (lanes 4–6 and 10–12) together with GST, GST-AKT or GST-14-3-3ζ. Cells were treated with vehicle (lanes 1–6) or with 100 nM of the
phosphatase inhibitor calyculin A (lanes 7–12) for 1 hour prior to harvesting. Cell lysates were analyzed directly (A) or following GST pull-down (B) for expression of FoxO3, S253-
phosphorylated-FoxO3, tubulin and GST-fusion proteins by immunoblotting. (C) HepG2 cells were transfected for 24 hours in duplicates with FHBE-Luciferase and RTK-Renilla
control vector together with pcDNA control vector, HA-FoxO3, HA-FoxO3 3XA, HA-FoxO3 P34A or HA-FoxO3 DNA BM (R211A/S253E, DNA-bindingmutant). Cells were incubated for
additional 24 hours with serum-free media (SFM) or with serum-free media supplemented with 20 μg/ml insulin (SFM+Ins) and analyzed for Luciferase activity using the Promega
Dual-Glo Luciferase assay system. For calculating the activity of each FoxO variant, the Luciferase/Renilla ratio obtained in samples transfected with pcDNA control vector was
subtracted from the values obtainedwith the FoxO variants. Each bar represented a single transfected sample. (D) HepG2 cells were transfected for 48 hours in duplicates with FHBE-
Luciferase and RTK-Renilla control vector together with pcDNA control vector, HA-FoxO3, HA-FoxO3 3XA, HA-FoxO3 P34A or HA-FoxO3 DNA BM (R211A/S253E, DNA-binding
mutant) and together with GST control, GST-AKT or GST-AKT K179M (an inactive ATP-binding pocket mutant) as indicated. Cells were analyzed for Luciferase activity and presented
are Luciferase/Renilla ratios. Each bar represented a single transfected sample.
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inability to detect association of phosphorylated FoxO3 with AKT,
suggesting that the complex dissociates following phosphorylation,
either through conformational change in FoxO3 or as a result of
displacement by 14-3-3.
Another novel aspect of this study is the demonstration that co-
expressing AKT with FoxO3 increases the steady-state levels of FoxO3
protein. This effect of AKT was not dependent on the FoxO3 RxRxxS/T
motifs and a fragment containing the ﬁrst 1–260 amino acids
exhibited the same increase as the full-length protein. It was,
however, dependent on having an intact AKT, since mutations of
AKT activation sites or the ATP binding pocket, which also abrogated
the binding of AKT to FoxO3, abolished the enhancement. Thus, since
FoxO3 phosphorylation itself was not needed for this enhancementand our AKT mutants were unable to distinguish between the binding
requirements and catalytic activity, the possibilities for this effect are
that AKT increases the protein levels through downstream signaling
events or through direct binding to FoxO3. Initial experiments
excluded the involvement of the mTORC1 complex, as rapamycin
treatment did not block this effect (data not shown). Elucidation of
the FoxO3 interaction point with AKT and vice versa may help in
addressing this question. AKT binding has been shown to decrease the
degradation of several of its targets, including PEA-15 and B23/NPM
[63,65], raising the possibility that also in the case of FoxO3, AKT may
be increasing the protein levels through direct binding rather than
downstream signaling events or a feedback mechanism. Nonetheless,
the observed increase in steady-state FoxO3 protein levels suggests a























Fig. 9. Amodel for FoxO3 regulation by AKT and 14-3-3. AKT activation by growth factors that activate the PI3K pathway induces AKT binding to FoxO3, resulting in increased steady-
state FoxO3 levels. Phosphorylated FoxO3 dissociates from AKT, possibly as a consequence of competition with 14-3-3. 14-3-3 binding to phosphorylated FoxO3 blocks its DNA
binding and transcriptional activity and also promotes its nuclear exclusion. In the cytoplasm, 14-3-3 binding inhibits FoxO3 dephosphorylation and degradation, thus maintaining a
pool that can be recycled. See text for more details.
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and FoxO protein expression has been observed in T cells: it has been
seen in two separate studies that AKT activation by PTEN deletion
correlated with increased FoxO protein levels [66], while inhibition of
AKT associated with decreased FoxO protein levels [67].
The regulation of FoxO proteins by 14-3-3 has been studied
extensively, establishing a negative regulatory role through blocking
their DNA binding and sequestering them in the cytoplasm [5,26–
28,43,68]. The results presented here show that 14-3-3 proteins can
also serve a positive regulatory role by increasing the steady-state
protein levels of phosphorylated and total FoxO3. This effect of 14-3-3
was dependent on the ability of 14-3-3 to bind FoxO3, since various
FoxO3 mutants impaired in 14-3-3 binding were not affected. The
stabilization involved primarily protection of phosphorylated FoxO3
from dephosphorylation at the AKT phosphorylation sites. Interest-
ingly, a positive role of 14-3-3 in protecting their targets from
proteolytic cleavage was observed in Arabidopsis [69] and 14-3-3 was
shown to protect FoxO1 degradation in vitro by Arabidopsis-derived
proteases. Our ﬁndings are also in agreement with the current
literature showing that signiﬁcant phosphorylated-FoxO protein
levels can be found in the cytoplasm, indicating that they are not
being immediately degraded. This observation suggests that there
may be a time frame in which phosphorylated-FoxO can be salvaged
through dephosphorylation and shuttled back into the nucleus
[58,70]. Therefore, the availability of unbound 14-3-3 in the cell,
which can bemodulated by various factors and cell conditions [57,71],
could affect the fate of phosphorylated FoxO3 to either stabilization
and recycling or degradation.
An important ﬁnding in this study was the observation that the
FoxO3 P34A mutant, which has a decreased capacity for 14-3-3
binding, but can be regulated by AKT in a similar fashion to the
wildtype, exhibited a constitutive transcriptional activity that could
not be inhibited even by the overexpression of AKT (Fig. 8D). This
ﬁnding suggests that 14-3-3 binding rather than AKT phosphorylation
itself serves as the key point in the negative regulation of FoxO3. This
view is in agreement with the results of Obsil et al. [27], showing thatFoxO4-14-3-3 binding motifs are necessary for the inhibition of
FoxO4–DNA binding. The signiﬁcance of this ﬁnding is that it suggests
that under stress conditions such as oxidative stress, where 14-3-3
proteins have been shown to undergo inactivating phosphorylation
by stress kinases such as JNK [72,73], FoxO proteins may be less prone
to negative regulation by AKT, since phosphorylated FoxO will still be
functional without having 14-3-3 exerting the negative regulation. It
remains to be determined whether under these conditions FoxO
proteins undergo rapid dephosphorylation and recycling, without
having 14-3-3 proteins protecting their dephosphorylation, or
whether they are subjected to accelerated degradation.
Overall, our data provide a more comprehensive view of FoxO3
regulation by AKT and 14-3-3 and suggest positive roles for both 14-3-
3 and AKT in FoxO3 regulation besides the previously described
negative regulatory roles.
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